Stereotactic Ablative Radiation Therapy for Unresectable Colorectal Oligometastases
| Autor: | Steven A. Burton, David A. Clump, David J. D'Ambrosio, Philip A. Sutera, Ronny Kalash, Dwight E. Heron, Alina Mihaela Mihai |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Subset Analysis
medicine.medical_specialty business.industry Colorectal cancer medicine.medical_treatment Cancer Phases of clinical research medicine.disease SABR volatility model 030218 nuclear medicine & medical imaging Radiation therapy Clinical trial 03 medical and health sciences 0302 clinical medicine Oncology 030220 oncology & carcinogenesis Gastrointestinal Cancer Medicine Radiology Nuclear Medicine and imaging Radiology business Prospective cohort study |
| Zdroj: | Advances in Radiation Oncology |
| ISSN: | 2452-1094 |
| Popis: | Purpose Patients with oligometastatic colorectal cancer have demonstrated excellent clinical outcomes with surgical resection of hepatic and pulmonary metastases. Stereotactic ablative radiation therapy (SABR) has emerged as an alternative local therapy for nonsurgical candidates. Herein, we report the oncologic and patient-reported quality-of-life (PR-QoL) outcomes for a subset of patients with oligometastatic colorectal cancer who were treated in a prospective phase 2 multicenter clinical trial. Methods and materials Patients with a pathologically proven diagnosis of oligometastatic colorectal cancer were enrolled as part of a prospective study. SABR dose and fractionation schedules were dependent on the lesion location and size. Patient follow-up occurred 6 weeks after completion of SABR and at 3-month intervals for the following 3 years. Patients received the Functional Assessment of Cancer Therapy-General questionnaire at baseline and at each follow-up visit to assess PR-QoL. The total Functional Assessment of Cancer Therapy-General questionnaire scores were compared with those from baseline using the Wilcoxon signed rank test. Overall survival, local progression-free survival (PFS), and distant PFS were calculated using the Kaplan-Meier estimation to the date of the last follow-up visit/death or local/distant failure. Results A total of 31 patients with oligometastatic colorectal cancer with 1 (71.0%), 2 (16.1%), 3 (3.2%), 4 (3.2%), or 5 (6.5%) metastatic lesions were identified. After a median follow-up time of 50.1 months, the median OS from the time of completion of the SABR was 53.9 months (95% confidence interval, 23.2-84.6), and the 5-year OS, local PFS, and distant PFS were 45%, 83%, and 27%, respectively. Acute grade 2+ toxicity was 9.7% (pain, nausea, fatigue) and late grade 3+ toxicity (small bowel obstruction) was 3.2% with no significant change in PR-QoL in the year after SABR. Conclusions This subset analysis of a prospective phase 2 study demonstrates that SABR is a safe and effective treatment option for patients with unresectable oligometastic colorectal cancer. In addition, SABR of oligometastatic disease preserves PR-QoL. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|